Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANL NASDAQ:AUTL NASDAQ:ETHZ NASDAQ:OCGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANLAdlai Nortye$10.99+3.7%$12.42$0.88▼$17.25$424M0.93113,528 shs25,603 shsAUTLAutolus Therapeutics$1.61-3.3%$1.59$1.18▼$2.70$441.82M2.021.27 million shs1.10 million shsETHZFlag Ship Acquisition$5.03-2.5%$4.52$0.70▼$17.46$95.63M1.176.44 million shs280,568 shsOCGNOcugen$1.39+0.7%$1.45$0.90▼$2.73$467.16M2.196.47 million shs6.53 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANLAdlai Nortye+1.92%+5.47%-11.07%+48.88%+657.09%AUTLAutolus Therapeutics+11.41%+11.41%-2.35%+24.81%-24.89%ETHZFlag Ship Acquisition+2.18%+0.39%+13.66%+75.51%+515,999,900.00%OCGNOcugen+6.98%+16.95%+2.99%-29.23%+40.66%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANLAdlai Nortye$10.99+3.7%$12.42$0.88▼$17.25$424M0.93113,528 shs25,603 shsAUTLAutolus Therapeutics$1.61-3.3%$1.59$1.18▼$2.70$441.82M2.021.27 million shs1.10 million shsETHZFlag Ship Acquisition$5.03-2.5%$4.52$0.70▼$17.46$95.63M1.176.44 million shs280,568 shsOCGNOcugen$1.39+0.7%$1.45$0.90▼$2.73$467.16M2.196.47 million shs6.53 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANLAdlai Nortye+1.92%+5.47%-11.07%+48.88%+657.09%AUTLAutolus Therapeutics+11.41%+11.41%-2.35%+24.81%-24.89%ETHZFlag Ship Acquisition+2.18%+0.39%+13.66%+75.51%+515,999,900.00%OCGNOcugen+6.98%+16.95%+2.99%-29.23%+40.66%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANLAdlai Nortye 2.67Moderate Buy$24.25120.66% UpsideAUTLAutolus Therapeutics 2.89Moderate Buy$8.75445.17% UpsideETHZFlag Ship Acquisition 1.00SellN/AN/AOCGNOcugen 2.60Moderate Buy$9.50583.45% UpsideCurrent Analyst Ratings BreakdownLatest ETHZ, ANL, OCGN, and AUTL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2026OCGNOcugen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/22/2026ANLAdlai Nortye Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight6/17/2026AUTLAutolus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/2/2026OCGNOcugen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/29/2026AUTLAutolus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/28/2026ANLAdlai Nortye OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$32.005/27/2026OCGNOcugen Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $11.005/18/2026OCGNOcugen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026AUTLAutolus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026ANLAdlai Nortye JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$22.005/14/2026AUTLAutolus Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $10.00(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANLAdlai Nortye$5M87.92N/AN/A($0.21) per share-52.33AUTLAutolus Therapeutics$75.39M5.67N/AN/A$0.67 per share2.40ETHZFlag Ship Acquisition$4.11M23.27N/AN/A$29.12 per share0.17OCGNOcugen$4.41M106.70N/AN/A($0.04) per share-34.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANLAdlai Nortye-$35.53MN/AN/AN/AN/AN/AN/AN/A8/6/2026 (Estimated)AUTLAutolus Therapeutics-$287.53M-$1.09N/AN/AN/A-311.98%-128.59%-46.25%8/11/2026 (Estimated)ETHZFlag Ship Acquisition-$6.17M-$159.65N/AN/AN/AN/A-185.71%-83.12%N/AOCGNOcugen-$67.85M-$0.24N/AN/AN/A-1,192.18%-127,987.80%-135.48%7/30/2026 (Estimated)Latest ETHZ, ANL, OCGN, and AUTL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026AUTLAutolus Therapeutics-$0.29-$0.27+$0.02-$0.27$26.27 million$26.22 million5/5/2026Q1 2026OCGNOcugen-$0.05-$0.06-$0.01-$0.06$0.42 million$1.53 million3/27/2026Q4 2025AUTLAutolus Therapeutics-$0.27-$0.34-$0.07-$0.34$23.92 million$24.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANLAdlai NortyeN/AN/AN/AN/AN/AAUTLAutolus TherapeuticsN/AN/AN/AN/AN/AETHZFlag Ship AcquisitionN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANLAdlai NortyeN/A0.650.65AUTLAutolus TherapeuticsN/A5.805.28ETHZFlag Ship Acquisition1.1110.0710.07OCGNOcugen4.171.861.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANLAdlai Nortye35.21%AUTLAutolus Therapeutics72.83%ETHZFlag Ship Acquisition4.07%OCGNOcugen10.27%Insider OwnershipCompanyInsider OwnershipANLAdlai NortyeN/AAUTLAutolus Therapeutics25.70%ETHZFlag Ship Acquisition15.10%OCGNOcugen3.95%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANLAdlai Nortye12740.00 millionN/ANot OptionableAUTLAutolus Therapeutics330266.16 million197.75 millionOptionableETHZFlag Ship Acquisition719.01 million16.14 millionN/AOCGNOcugen80338.52 million325.15 millionOptionableETHZ, ANL, OCGN, and AUTL HeadlinesRecent News About These CompaniesOcugen Inc. stock rises Tuesday, outperforms marketJune 24 at 8:55 AM | marketwatch.comOcugen (NASDAQ:OCGN) CFO Treerita Essali Johnson-Greene Acquires 21,000 SharesJune 18, 2026 | insidertrades.comHow The Ocugen (OCGN) Investment Story Is Evolving Without New Analyst GuidanceJune 5, 2026 | finance.yahoo.comWhy Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?June 4, 2026 | finance.yahoo.comWhy Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?June 4, 2026 | zacks.comOcugen Consolidates Financial Leadership Under New Accounting OfficerJune 3, 2026 | tipranks.comOcugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage CareJune 3, 2026 | zacks.comIs OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data?June 3, 2026 | zacks.comOCGN's Catalyst Calendar for Trial Data and Filings Through 2028June 3, 2026 | zacks.comOcugen to Participate in Upcoming June Investor and Industry ConferencesJune 2, 2026 | finance.yahoo.comOcugen to Participate in Upcoming June Investor and Industry ConferencesJune 2, 2026 | globenewswire.comOcugen, Assertio among healthcare stocks set to join Russell Microcap; Definium Therapeutics, Tvardi Therapeutics to exitMay 26, 2026 | msn.comOcugen Announces Interim Chief Medical Officer Appointment TransitionMay 14, 2026 | tipranks.comOcugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior NotesMay 14, 2026 | finance.yahoo.comOcugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior NotesMay 14, 2026 | globenewswire.com3 Reasons Not to Buy Into the Hantavirus-Related Biotech RallyMay 13, 2026 | fool.comOcugen (OCGN) Reports Q1 EPSMay 13, 2026 | finance.yahoo.comOcugen to Participate in Upcoming May Scientific and Investor ConferencesMay 13, 2026 | finance.yahoo.comOcugen, Inc. to Present Innovative Modifier Gene Therapy Platform at May 2026 ConferencesMay 13, 2026 | quiverquant.comQOcugen to Participate in Upcoming May Scientific and Investor ConferencesMay 13, 2026 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 20265 Under-the-Radar AI Stocks to Watch in JuneBy Thomas Hughes | May 31, 2026Will the SpaceX IPO Put These 5 Public Space Stocks Into a Higher Orbit?By Ryan Hasson | June 2, 20263 Dividend Kings With Income, Stability, and a Possible CatalystBy Chris Markoch | June 16, 2026Father's Day Investing: 3 Stocks Built for Long-Term ReturnsBy Chris Markoch | June 16, 2026ETHZ, ANL, OCGN, and AUTL Company DescriptionsAdlai Nortye NASDAQ:ANL$10.99 +0.39 (+3.68%) Closing price 04:00 PM EasternExtended Trading$10.88 -0.12 (-1.05%) As of 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.Autolus Therapeutics NASDAQ:AUTL$1.60 -0.06 (-3.31%) Closing price 03:59 PM EasternExtended Trading$1.62 +0.01 (+0.87%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Flag Ship Acquisition NASDAQ:ETHZ$5.03 -0.13 (-2.52%) As of 06/23/20261180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.Ocugen NASDAQ:OCGN$1.39 +0.01 (+0.72%) Closing price 04:00 PM EasternExtended Trading$1.42 +0.03 (+1.80%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why KB Home Could Reward Patient Investors Later Tesla's New NHTSA Probe Lands at the Worst Possible Time Meta's Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time ASML’s Chip Dominance Runs Into New Silicon Boundaries Frozen Assets: How Super Micro Puts AI Heat on Ice The SpaceX Sell-Off May Be More Than a Market Overreaction Why These South Korea-Focused ETFs Have More Than Doubled in 2026 Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
